JP2012509283A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509283A5
JP2012509283A5 JP2011536703A JP2011536703A JP2012509283A5 JP 2012509283 A5 JP2012509283 A5 JP 2012509283A5 JP 2011536703 A JP2011536703 A JP 2011536703A JP 2011536703 A JP2011536703 A JP 2011536703A JP 2012509283 A5 JP2012509283 A5 JP 2012509283A5
Authority
JP
Japan
Prior art keywords
cells
pancreatic
pharmaceutical composition
stro
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509283A (ja
JP5891034B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/001511 external-priority patent/WO2010057260A1/en
Publication of JP2012509283A publication Critical patent/JP2012509283A/ja
Publication of JP2012509283A5 publication Critical patent/JP2012509283A5/ja
Application granted granted Critical
Publication of JP5891034B2 publication Critical patent/JP5891034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536703A 2008-11-20 2009-11-19 膵機能障害の治療または予防方法 Active JP5891034B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19979608P 2008-11-20 2008-11-20
US61/199,796 2008-11-20
PCT/AU2009/001511 WO2010057260A1 (en) 2008-11-20 2009-11-19 Method for treating or preventing a pancreatic dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015111995A Division JP6499016B2 (ja) 2008-11-20 2015-06-02 膵機能障害の治療または予防方法

Publications (3)

Publication Number Publication Date
JP2012509283A JP2012509283A (ja) 2012-04-19
JP2012509283A5 true JP2012509283A5 (enExample) 2012-12-20
JP5891034B2 JP5891034B2 (ja) 2016-03-22

Family

ID=42197754

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011536703A Active JP5891034B2 (ja) 2008-11-20 2009-11-19 膵機能障害の治療または予防方法
JP2015111995A Active JP6499016B2 (ja) 2008-11-20 2015-06-02 膵機能障害の治療または予防方法
JP2017112578A Withdrawn JP2017214384A (ja) 2008-11-20 2017-06-07 膵機能障害の治療または予防方法
JP2019162845A Active JP7051770B2 (ja) 2008-11-20 2019-09-06 膵機能障害の治療または予防方法
JP2021177234A Withdrawn JP2022031662A (ja) 2008-11-20 2021-10-29 膵機能障害の治療または予防方法
JP2023086994A Active JP7751607B2 (ja) 2008-11-20 2023-05-26 膵機能障害の治療または予防方法
JP2025099335A Pending JP2025148353A (ja) 2008-11-20 2025-06-13 膵機能障害の治療または予防方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2015111995A Active JP6499016B2 (ja) 2008-11-20 2015-06-02 膵機能障害の治療または予防方法
JP2017112578A Withdrawn JP2017214384A (ja) 2008-11-20 2017-06-07 膵機能障害の治療または予防方法
JP2019162845A Active JP7051770B2 (ja) 2008-11-20 2019-09-06 膵機能障害の治療または予防方法
JP2021177234A Withdrawn JP2022031662A (ja) 2008-11-20 2021-10-29 膵機能障害の治療または予防方法
JP2023086994A Active JP7751607B2 (ja) 2008-11-20 2023-05-26 膵機能障害の治療または予防方法
JP2025099335A Pending JP2025148353A (ja) 2008-11-20 2025-06-13 膵機能障害の治療または予防方法

Country Status (10)

Country Link
US (3) US8894972B2 (enExample)
EP (2) EP2350266B1 (enExample)
JP (7) JP5891034B2 (enExample)
KR (2) KR101832497B1 (enExample)
CN (3) CN103800370B (enExample)
AU (1) AU2009317874B2 (enExample)
CA (1) CA2744228C (enExample)
DK (1) DK2350266T3 (enExample)
ES (2) ES2550795T3 (enExample)
WO (1) WO2010057260A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2046349T3 (en) * 2006-07-12 2015-12-21 Mesoblast Inc TREATMENT OF EXCESSIVE NEOVASCULARIZATION
AU2009317874B2 (en) 2008-11-20 2016-04-21 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
CN107141353A (zh) 2009-03-05 2017-09-08 哈佛学院董事会 分泌的aP2及其抑制方法
ES2665328T3 (es) 2010-07-02 2018-04-25 Mesoblast, Inc. Células que expresan STRO-1bright para tratar la enfermedad de injerto contra huésped
EP2709634B1 (en) * 2011-05-19 2020-09-09 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
CN103841983B (zh) * 2011-06-03 2018-11-02 麦瑟布莱斯特公司 治疗或预防神经性疾病的方法
EP3653218B1 (en) * 2011-07-04 2024-12-18 Mesoblast, Inc. Treating or preventing rheumatic disease
CA2840307C (en) 2011-07-06 2021-10-19 Cell Therapy Limited Progenitor cells of mesodermal lineage
CN104098682B (zh) * 2013-04-03 2018-01-02 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CA2893942C (en) * 2012-12-12 2023-03-28 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
US20140314872A1 (en) * 2013-04-22 2014-10-23 Hans Klingemann Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction
CN104714021B (zh) * 2013-12-12 2016-05-25 张曼 尿液凝血酶原蛋白在2型糖尿病合并冠心病中的应用
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
EA201990136A1 (ru) * 2016-06-27 2019-05-31 Президент Энд Феллоуз Оф Гарвард Колледж Соединения, применимые для лечения нарушений обмена веществ
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
CN110959579A (zh) * 2019-11-14 2020-04-07 顾隽 患者来源的淋巴瘤免疫缺陷小鼠移植瘤模型的构建方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
AU2003262628A1 (en) * 2002-08-14 2004-03-03 University Of Florida Bone marrow cell differentiation
DE602004030823D1 (de) * 2003-11-04 2011-02-10 Biomaster Inc Verfahren und system zur herstellung von stammzellen aus fettgewebe
CA2580975A1 (en) * 2004-09-24 2006-03-30 Angioblast Systems, Inc. Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
DK1869165T3 (en) * 2005-04-12 2016-02-01 Mesoblast Inc Isolation of Adult Multipotent Cells by Tissue-Specific Alkaline Phosphate
GB0514785D0 (en) * 2005-07-19 2005-08-24 Innovia Films Ltd Sealed ream wrap package and films suitable for forming such packages
JP2009535347A (ja) * 2006-04-28 2009-10-01 テュレーン・ユニバーシティ・ヘルス・サイエンシーズ・センター 糖尿病の治療方法
EP2117543A4 (en) * 2007-02-01 2011-09-28 Nephrogen Llc POTENTIALIZATION OF THE IMPLANTATION OF STEM CELLS AND TREATMENT OF ORGAN DYSFUNCTION OR BODY INSUFFICIENCY
AU2009317874B2 (en) 2008-11-20 2016-04-21 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Similar Documents

Publication Publication Date Title
JP7751607B2 (ja) 膵機能障害の治療または予防方法
Zang et al. Mesenchymal stem cell therapy in type 2 diabetes mellitus
Gao et al. Mesenchymal stem cells (MSCs): a novel therapy for type 2 diabetes
JP2017214384A5 (enExample)
JP2022031662A5 (enExample)
JP2006506386A5 (enExample)
WO2014075589A1 (zh) 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用
Muchmore et al. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase
JP2016519127A (ja) 新規投与レジメン
CN106279400A (zh) P8降糖肽的设计及其用途
JP2020502140A5 (enExample)
JP2020510628A5 (enExample)
EP3142686A2 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
Asaad et al. Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics
Marques et al. GLP-1 analogue-loaded glucose-responsive nanoparticles as allies of stem cell therapies for the treatment of type I diabetes
CN106519016A (zh) 降糖调脂肽——Progly肽的设计及其用途
US9914910B2 (en) Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1
L'Heureux et al. Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2
Lau et al. Charting the next century of insulin replacement with cell and gene therapies
WO2018148666A1 (en) Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
JP2007513059A5 (enExample)
Krempf et al. Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients.
George Future trends in diabetes management.
Rao et al. Transplantation of Pancreatic Islets
Singh et al. Transplanting fragments of diabetic pancreas into activated omentum gives rise to new insulin producing cells